Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Jiang M, Kang Y, Sewastianik T, Wang J, Tanton H, Alder K, et al. BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins. Nat Commun. 2020;11(1):19.

Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020;8(1):108-119.

Satlin MJ, Westblade LF, Lee JR. Avoiding infections in transplant recipients: does the gut microbiota have a key role? Expert Rev Clin Immunol. 2020;16(2):113-115.

Deng Z, Ng C, Inoue K, Chen Z, Xia Y, Hu X, et al. Def6 regulates endogenous type-I interferon responses in osteoblasts and suppresses osteogenesis. Elife. 2020;9.

van der Mijn JC, Fu L, Khani F, Zhang T, Molina AM, Barbieri CE, et al. Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. Transl Oncol. 2020;13(2):177-185.

Mesa H, Manivel JC, Larson WS, Dachel SK, Reinink AR, Jessurun J. Immunophenotypic Comparison of Neoplasms of the Appendix, Right Colon, and Left Colon in Search of a Site-Specific Phenotypic Signature. Int J Surg Pathol. 2020;28(1):20-30.

Wang K, Huang X, Di Liberto M, Chen-Kiang S. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy. Hematol Oncol Clin North Am. 2020;34(5):809-823.

Pierson SK, Khor JS, Ziglar J, Liu A, Floess K, NaPier E, et al. ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Rep Med. 2020;1(9):100158.

Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20(6):323-342.

Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020;10(3):440-459.